Gargiulo Luigi, Ibba Luciano, Pavia Giulia, Avagliano Jessica, Cortese Andrea, Costanzo Antonio, Narcisi Alessandra
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.
Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
J Dermatolog Treat. 2023 Dec;34(1):2183729. doi: 10.1080/09546634.2023.2183729.
The overlap of psoriasis and atopic dermatitis (AD) is rare and treating moderate-to-severe cases can be challenging. Conventional immune-suppressive drugs cannot be used long-term, and no biological drugs are currently approved for treating both conditions. We report the cases of four patients with overlapping features of both psoriasis and AD. After being treated with several systemic drugs, including gold-standard treatments for both psoriasis and AD, they received upadacitinib 15 or 30 mg, achieving complete remission. Upadacitinib is an inhibitor of Janus Kinase 1, currently approved for treating moderate-to-severe AD. To date, very limited data are available regarding the efficacy of upadacitinib in psoriasis. In a phase-3 trial on the efficacy of upadacitinib 15 mg in patients affected by psoriatic arthritis, 52.3% of patients achieved a 75% improvement in Psoriasis Area and Severity Index (PASI75) after one year. Currently, no clinical trials are evaluating the efficacy of upadacitinib in plaque psoriasis.
银屑病和特应性皮炎（AD）的重叠情况罕见，治疗中重度病例可能具有挑战性。传统的免疫抑制药物不能长期使用，目前尚无获批用于治疗这两种病症的生物药物。我们报告了4例具有银屑病和AD重叠特征的患者病例。在用包括银屑病和AD的金标准治疗在内的几种全身药物治疗后，他们接受了15或30毫克的乌帕替尼治疗，实现了完全缓解。乌帕替尼是一种Janus激酶1抑制剂，目前已获批用于治疗中重度AD。迄今为止，关于乌帕替尼在银屑病中的疗效的数据非常有限。在一项关于15毫克乌帕替尼对银屑病关节炎患者疗效的3期试验中，52.3%的患者在一年后银屑病面积和严重程度指数（PASI75）改善了75%。目前，尚无临床试验评估乌帕替尼在斑块状银屑病中的疗效。
